Abstract Body

Background: The intrahepatic endogenous interferon response fails to promote hepatitis C virus (HCV) clearance once chronic infection is established. The interferon (IFN)-stimulated chemokine CXCL10 (IP-10) is hepatically produced in chronic infection. A short CXCL10 isoform with antagonistic properties is generated by DPP4 activity, and likely contributes to impaired immunity in chronic HCV infection. We previously showed that IFN-free treatment of chronic HCV with sofosbuvir and ribavirin (SOF/RBV) is accompanied by rapid down-regulation of endogenous interferon activity. There was a trend towards higher pre-treatment CXCL10 levels in eventual relapsers (p=0.12, 994 pg/ml SVR (n=28), 1249 pg/ml relapsers (n=14)). Here, we examined how antagonistic, agonistic, and total CXCL10 levels and DPP4 activity changed during therapy, and whether they were associated with treatment outcome.

Methods: Serum was analyzed from patients who achieved SVR (n=11) or who relapsed (n=10) after treatment with 24 weeks of SOF/RBV on the NIH/NIAID SPARE trial (NCT01441180). Total, antagonistic, and agonistic CXCL10 was measured by Simoa (Quanterix) assay in triplicate at day 0, day 7, and week 20 of treatment. DPP4 levels were measured by ELISA and activity by DPP-Glo™ Protease assay (Promega). Data were analyzed by the Mann Whitney t-test or by Pearson correlation using Prism 6.0 software.

Results: In this cohort of patients, agonist (p=0.038) and total (p=0.0079) CXCL10 were significantly higher pre-treatment in patients who later relapsed, while the N-terminal truncated form of CXCL10 did not differ (p=0.31). All forms of CXCL10 decreased rapidly on treatment irrespective of treatment outcome. DPP4 activity correlated with pre-treatment levels of antagonistic CXCL10 (p=0.0027), but not agonistic or total CXCL10. Interestingly, there was no change in DPP4 activity or levels by week 1 of treatment, when all CXCL10 isoforms had declined, while activity had declined by week 20 of treatment. In patients who relapsed, CXCL10 concentration and DPP4 activity returned to pre-treatment levels.

Conclusions: Pre-treatment total and agonistic CXCL10, but not the antagonistic DPP4 cleavage product, were associated with treatment outcome in this subset of patients. The delayed kinetic decline of DPP4 activity relative to CXCL10 expression suggests the DPP4 pathway is not immediately regulated by endogenous interferon, providing insight into hepatic immune regulation during IFN-free HCV therapy.